Caffeine; the Forgotten Potential for Parkinson's Disease

Author(s): Ahmed Negida* , Mohamed Elfil , Attia Attia , Eslam Farahat , Mohamed Gabr , Ahmed Essam , Doaa Attia , Hussein Ahmed .

Journal Name: CNS & Neurological Disorders - Drug Targets

Volume 16 , Issue 6 , 2017

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Parkinson’s disease (PD) is the second most common neurological disorder characterized by loss of dopaminergic fibers in the basal ganglia and presence of Lewy bodies.

Method and Results: The literature suggests that caffeine plays multiple roles in PD. Epidemiological studies showed that caffeine intake was associated with less risk of developing PD, especially in genetically susceptible patients. On the level of Lewy bodies' formation, caffeine binds to α-synuclein protein inducing conformational changes and preventing their aggregation. On the level of mitochondrial stress, caffeine acts as an antioxidant that reduces oxidative stress in PD and therefore, slows the progression of the disease. On the level of dopamine release, the literature suggests that caffeine increases dopamine release and the number of dopamine receptors in the striatum via A2a receptor antagonism.

Conclusion: As an adjuvant treatment, caffeine interacts with antiparkinsonian medications and can alter levodopa pharmacokinetics, reduce dyskinesia, and improve gait in patients with freezing of gait. In this review, we discussed the potential of caffeine as a possible neuroprotective agent and as an addon therapy for PD.

Keywords: Adenosine receptors, Caffeine, Dopamine, Lewy bodies, Parkinson's disease, tremors.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 6
Year: 2017
Page: [652 - 657]
Pages: 6
DOI: 10.2174/1871527315666161107091149
Price: $58

Article Metrics

PDF: 35
HTML: 3
EPUB: 1